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Recently we found that acute treatment with Oxotremorine (Oxo), a non-selective mAChRs agonist, 
up-regulates heat shock proteins and activates their transcription factor heat shock factor 1 in the 
rat hippocampus. Here we aimed to investigate: a) if acute treatment with Oxo may regulate pro-
inflammatory or anti-inflammatory cytokines and oxidative stress in the rat hippocampus; b) if chronic 
restraint stress (CRS) induces inflammatory or oxidative alterations in the hippocampus and whether 
such alterations may be affected by chronic treatment with Oxo. In the acute experiment, rats were 
injected with single dose of Oxo (0.4 mg/kg) and sacrificed at 24 h, 48 h and 72 h. In the CRS experiment, 
the rats were exposed for 21 days to the CRS and then were treated with Oxo (0.2 mg/kg) for further 
10 days. The acute Oxo treatment showed an ability to significantly reduce reactive oxygen species 
(ROS), singlet oxygen (1o2), pro-inflammatory cytokines levels (IL-1β and IL-6) and phosphorylated 
nf-κB-p65. Acute Oxo treatment also increased superoxide dismutase (SOD)-2 protein levels and 
stimulated SOD activity. No differences were detected in the anti-inflammatory cytokine levels, 
including IL-10 and TGF-β1. In the group of rats exposed to the CRS were found increased hippocampal 
IL-1β and IL-6 levels, together with a reduction of SOD activity level. These changes produced by CRS 
were counteracted by chronic Oxo treatment. In contrast, the upregulation of ROS and 1o2 levels in the 
CRS group was not counteracted by chronic Oxo treatment. The results revealed a hippocampal anti-
inflammatory and antioxidant effect of Oxo treatment in both basal conditions and anti-inflammatory 
in the CRS rat model.
Several reports have showed that cholinergic system in the brain may modulate several function, including 
neurogenesis, neuroprotection, neuronal differentiation and plasticity1–5. The family of muscarinic acetylcho-
line receptors (mAChRs) is composed of five subtypes (M1R-M5R), with M1R and M3R highly expressed in the 
hippocampus, where they regulate neuronal plasticity, neuroprotection, cognitive functions and behaviors1,6,7. 
Recently, we found that the non-selective mAChRs agonist Oxotremorine (Oxo) may transactivate the fibroblast 
growth factor receptor (FGFR) and increase neurite outgrowth in the hippocampal primary neuronal cultures8. 
More recently, we evidenced that Oxo treatment recovered rats from the stress-induced anxiety-like behavior, 
and restored fibroblast growth factor 2 (FGF2) and brain derived neurotrophic factor (BDNF) levels in ventral 
hippocampus and prefrontal cortex7, two brain regions considered responsible of chronic restraint stress (CRS) 
induced anxiety. In another work, we found that Oxo up-regulates heat shock proteins and activates their tran-
scription factor heat shock factor 1 (HSF1) in the rat hippocampus9. Heat shock proteins, in addition to their 
importance in protecting neurons from protein mis-folding and aggregation, are also regulators of inflammation 
and oxidative stress10.
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In the present work we aimed to investigate if mAChR may regulate in the rat hippocampus pro-inflammatory 
or anti-inflammatory cytokines and responses to oxidative stress. Concerning the involvement of mAChR acti-
vation in the inflammatory response, only two papers are available and both reported scopolamine-mediated 
increase of tumor necrosis factor-α (TNF-α) and stimulation of transcription factor nuclear factor-kB-p65 
(NF-κB-p65) pathway in the rat hippocampus11 and in immortalized murine microglia BV-2 cells12. Since both 
investigations have used scopolamine, it is not clear if cholinergic neurotransmission activation is responsible 
for anti-inflammatory effects or if other neurotransmitters are involved as consequence of mAChRs inhibition. 
For example Young Jin Jang et al.11 reported that decaffeinated coffee counteracted the hippocampal increase 
of TNF-α and phosphorylation of inhibitor protein-κBα and NF-κB-p65 induced by scopolamine treatment. 
Similarly, Jung et al.12 reported that mangiferin, a compound with pleiotropic function including inhibition of 
Acetylcholinesterase, may counteract the effects of scopolamine. Concerning the role of mAChRs in neuronal 
response to oxidative stress, there are few discordant data. Indeed, some data reported that mAChR activation 
increases neuronal vulnerability to oxidative stress13, while others outlined that mAChR stimulation can induce 
reactive oxygen species (ROS), which may be involved, as second messengers, in cell-signaling pathways14,15.
Recent studies have developed lots of data concerning the stress-induced anxiety-depression and genera-
tion of hippocampal inflammation and oxidative stress. In this context, several reports have shown increased 
levels of cytokines, such as interleukin-1β (IL-1β) and interleukin-6 (IL-6) in experimental models of 
anxiety-depression16. Indeed, prolonged restrain stress causes increase of IL-617, and chronic stress18 or social 
stress19 may induce neuroinflammation by increasing NF-κB20,21 and IL-1β in the brain22. Interestingly, knockout 
mice for IL-6 gene expression showed protection against stress-induced anxiety-depression-like behaviors23. In 
addition to inflammation, oxidative stress has also been showed to take part in the anxiety-depression and other 
psychiatric disorders24–26. During chronic stress, overproduction of ROS induces oxidative process dysregula-
tion, producing neuronal damage27. The protection against oxidative stress needs antioxidant enzymes such as 
superoxide dismutase (SOD), which catalyze the dismutation of superoxide anion (O2−) to oxygen and hydrogen 
peroxide (H2O2). In this context, Möller et al.28 reported that post-weaning social isolation induces SOD activity 
in the brain, whereas the treatment with antipsychotic clozapine counteracts both the behavioral alterations and 
changes of redox activity.
According to the hypothesis of inflammatory and oxidative damage involvement in stress- induced 
anxiety-depression, the antidepressant effect of several drugs has been linked to a reduction of pro-inflammatory 
cytokines in the rat hippocampus29. In this context, antidepressant effect of ketamine has been attributed to both 
inhibition of pro-inflammatory responses30,31 and the upregulation in hippocampal levels of IL-6 and IL-1β, prob-
ably in relation to different treatment protocols32. Treatment with agonist of β-adrenergic receptors in stressed 
animals increases the expression of IL-1β in the brain33,34, whereas β-adrenergic receptor antagonist counteracts 
anxiety and activation of microglia produced by repeated social defeat35. Moreover, the antidepressant fluoxetine 
may reduce the levels of pro-inflammatory cytokines, including IL-1β36. Based on published data and our find-
ings reporting the effects of Oxo treatment in reducing the anxiety-like behavior induced by CRS7, in the present 
work we aimed to examine whether our model of CRS-induced anxiety-like behavior shows pro-inflammatory 
or oxidative alterations in the hippocampus and whether such alterations may be affected by treatment with Oxo. 
In order to verify the involvement of mAChR receptors activation in pro-inflammatory or anti-inflammatory 
cytokines regulation we have chosen to accurately investigate, by time-course analysis, the effects of acute treat-
ment with Oxo, a potent non-selective mAChR agonist, on cytokines levels. For this purpose, we have analyzed 
two canonic pro-inflammatory cytokines, IL-1β and IL-6, and two anti-inflammatory cytokines, interleukin-10 
(IL-10) and transforming growth factor β1 (TGF-β1). In addition, we have also analyzed the effects of Oxo on the 
NF-κB, ROS levels, cytosolic SOD (SOD1) and mitochondrial SOD (SOD2) both as protein and activity levels. 
In addition, as mentioned above, we examined whether inflammatory or oxidative alterations were present in the 
hippocampus of rats exposed to CRS and whether such alterations were affected by chronic treatment with Oxo.
Results
Cortisol levels. Among the glucocorticoid regulating the stress responses in rodents, we have analyzed cor-
tisol levels instead of corticosterone levels, widely used in literature, according with previous studies showing 
similarity between cortisol and corticosterone levels37.
Cortisol levels in rats after acute Oxo treatment. The results of the cortisol levels after acute Oxo treatment 
(0.4 mg/kg) are reported in Fig. 1D. The analysis of cortisol levels showed a trend of reduction in all the examined 
time-points, but in none of them it becomes significant as compared to control group.
Cortisol levels in rats exposed to CRS and their regulation by chronic Oxo treatment. The results of cortisol lev-
els in rats exposed to CRS and related effects of chronic Oxo treatment are reported in Fig. 1E. The analysis of 
cortisol levels showed a trend of increase in all experimental groups, but no significance was found for stress 
effect (F(1,28) = 0.827, p > 0.05), nor for Oxo treatment (F(1,28) = 1.48, p > 0.05) and interaction (stress × treatment: 
F(1,28) = 0.057, p = 0.81).
Oxo effect on pro-inflammatory and anti-inflammatory cytokine levels in the rat hippocampus. 
In order to study the effects of Oxo treatment on hippocampal pro-inflammatory and anti-inflammatory 
cytokines levels, we performed an acute treatment with Oxo at dose of 0.4 mg/kg and rats were killed at three 
different time points (24 h, 48 h and 72 h) after Oxo treatment. The experimental design is schematized in Fig. 1A. 
The levels of pro-inflammatory cytokines, IL-1β and IL-6, measured by ELISA kit, were found significantly 
reduced at 48 h and 72 h after acute Oxo treatment (Fig. 2A,B). The levels of anti-inflammatory cytokines, includ-
ing IL-10 and TGF-β1, were not affected by acute Oxo treatment in any examined time-points (Fig. 2C,D).
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Next, we examined the transcription factor NF-κB, which is extensively studied for its role in regulating 
expression of IL-1β and IL-6. The NF-κB-p65 subunit protein levels were found unchanged (Fig. 3A), whereas 
phosphorylation of NF-κB-p65 (pNF-κB-p65) resulted significantly decreased at 72 h after acute Oxo treatment 
(Fig. 3B).
Oxo effect on ROS levels, SOD1 and SOD2 proteins and activity levels in the rat hippocampus. 
In this study, the ability of Oxo to affect oxidative stress in the hippocampus was evaluated by detecting ROS 
levels and SOD activity. Global ROS levels, detected using DCFH-DA assay, showed a significant reduction at 
Figure 1. Schedule of treatment experimental procedures and serum cortisol levels. (A) Experimental schedule 
of time-course treatment with single injection of Oxo (0.4 mg/kg) or saline (Ctrl, vehicle) and sacrifice after 24 h, 
48 h and 72 h. (B) Pretreatment with 1 mg/kg of scopolamine 20 min before single injection of Oxo treatment 
(0.4 mg/kg) or single injection of Oxo and sacrifice after 72 h. (C) Experimental schedule of chronic restraint 
stress (CRS) for 21 days, chronic treatment with Oxo (0.2 mg/kg) for 10 days and sacrifice after 4 days. (D) 
Quantitative analysis of serum cortisol levels after single injection of Oxo (0.4 mg/kg) and sacrifice at different 
time points (24 h, 48 h and 72 h). (E) Quantitative analysis of serum cortisol levels after CRS and chronic 
treatment with Oxo (0.2 mg/kg) for 10 days. Data in (D,E) represent Mean ± S.E.M.
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all the studied time points following acute Oxo treatment (Fig. 4A). Among ROS, the selective evaluation of 1O2 
species levels, detected using SOSG assay, also showed a significant reduction at all the studied time points after 
acute Oxo treatment (Fig. 4B). Therefore, the selective analysis of 1O2 species levels showed a similar pattern of 
global ROS levels. Next, we examined SOD1 and SOD2 protein levels and we found a significant increase of SOD2 
at 72 h, whereas SOD1 was found unchanged at all the studied time points (Fig. 4C,D). The evaluation of SOD 
activity level revealed a significant increase at 48 h and 72 h after acute Oxo treatment (Fig. 4E). This increase of 
SOD activity level was in good correlation with the upregulation of SOD2 protein levels and with ROS reduction 
at 72 h after Oxo treatment.
mAChR antagonist scopolamine pretreatment on Oxo effects. The specificity of the observed acute 
Oxo effects was verified using pretreatment with the non-selective mAChR antagonist scopolamine (1 mg/kg) 
administered 20 min before Oxo injection (0.4 mg/kg). The experimental design is schematized in Fig. 1B. For 
this study was used the time point of 72 h after Oxo treatment. The results showed that scopolamine completely 
blocked Oxo effects on IL-1β and IL-6 protein levels (Fig. 2A,B). The levels of IL-10 and TGF-β1, already not 
influenced by acute Oxo treatment, did not show any modifications following pretreatment with scopolamine 
(Fig. 2C,D). Similarly, scopolamine pretreatment completely blocked the ability of Oxo to reduce oxidative stress, 
by counteracting the increase of both SOD2 protein levels and SOD activity and restoring ROS and 1O2 levels 
(Fig. 4). The group treated with scopolamine alone (1 mg/kg) did not show significant changes in all the examined 
cytokines protein levels and in ROS or 1O2 production or SOD1 and SOD2 protein levels, including SOD activity 
(Figs 2 and 4).
Cytokine levels in the hippocampus of rats exposed to CRS and their regulation by chronic Oxo 
treatment. Recently, as mentioned above, have been developed a lot of data concerning the stress-induced 
anxiety-depression and generation of hippocampal inflammation and oxidative stress. Accordingly, the effectiveness 
of some anxiolytic-antidepressant compounds, including Oxo, has been associated to the reduction of cytokines and 
oxidative stress in the hippocampus. Therefore, in the present work we examined whether CRS was characterized 
by hippocampal changes of inflammatory cytokines levels or oxidative stress and, consequently, if such alterations 
Figure 2. Oxo effect on pro-and anti-inflammatory cytokines protein levels in the hippocampus. ELISA 
analysis of IL-1β (A) and IL-6 (B) protein levels at different time-points (24 h, 48 h and 72 h) after acute Oxo 
treatment revealed a significant decrease at 48 h and 72 h as compared to control group (Ctrl). Scopolamine 
(Scop), injected 20 min before acute Oxo treatment, completely blocked Oxo effect. Scopolamine alone did 
not show significant changes of both IL-1β and IL-6. The ELISA analysis of IL-10 (C) and TGF-β1 (D) protein 
levels did not show significant variation in all experimental groups. Data are reported as means ± SE. PLSD: 
**P < 0.01, ****P < 0.0001.
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would be affected by chronic treatment with Oxo. The experimental design is schematized in Fig. 1C. The results 
showed that pro-inflammatory cytokines, IL-1β and IL-6, were significantly up-regulated in the CRS group (stress 
effect: IL-1β, F(1,16) = 8.8, p < 0.02; IL-6, F(1,16) = 10.4, p < 0.02), and that this increase was blocked by chronic Oxo 
treatment (treatment effect: IL-1β, F(1,16) = 4.0, p = 0.8; IL-6, F(1,16) = 3.2, p = 0.11) (stress × treatment effect: IL-1β, 
F(1,16) = 2.26, p = 0.17; IL-6, F(1,16) = 17.26, p < 0.01) (Fig. 5A,B). However, IL-1β and IL-6 levels in the group treated 
with chronic Oxo alone have not changed in comparison to control group, contrarily to reduction observed with 
acute Oxo treatment. The anti-inflammatory cytokines, TGF-β1 (treatment effect: F(1,16) = 0.17, p = 0.69; stress 
effect: F(1,16) = 0.2, p = 0.66; stress × treatment effect: F(1,16) = 0.38, p = 0.55) and IL-10 (treatment effect: F(1,16) = 1.22, 
p = 0.3; stress effect: F(1,16) = 0.3, p = 0.12; stress × treatment effect: F(1,16) = 0.73, p = 0.42), and the NF-κB-p65 pro-
tein levels did not show significant changes (treatment effect: F(1,15) = 0.55, p = 0.47; stress effect: F(1,15) = 4.1, p = 0.06; 
stress × treatment effect: F(1,15) = 0.119, p = 0.66) in all experimental groups (Fig. 5C–E).
Oxidative stress levels in the hippocampus of rats exposed to CRS and their regulation by chronic 
Oxo treatment. According to experimental studies reporting the effects of oxidative stress in anxiety and 
depression pathogenesis38, here we detected a significant increase of global ROS levels in the CRS group (stress effect: 
F(1,16) = 49.8, p = 0.0001) (Fig. 6A). However, chronic treatment of CRS group with Oxo failed to counteract this global 
ROS increase (treatment effect: F(1,16) = 4.6, p = 0.64). In the group treated with chronic Oxo alone the global ROS levels 
although increased did not reach significance, revealing that chronic Oxo treatment did not show any inhibitory effects 
on ROS levels (stress × treatment effect: F(1,16) = 1.02, p = 0.34) (Fig. 6A), contrarily to what was observed with acute 
Oxo treatment (Fig. 4A). The selective analysis of 1O2 species levels showed a similar pattern of global ROS levels, with 
the achievement of significant increase even in the group treated with Oxo alone (stress effect: F(1,16) = 49.2, p < 0.0001; 
treatment effect: F(1,16) = 18.7, p < 0.01; stress × treatment effect: F(1,16) = 7.1, p = 0.024) (Fig. 6B).
SOD1 and SOD2 protein levels were found unchanged in all experimental groups (SOD1: stress effect: 
F(1,16) = 4.44, p = 0.51; treatment effect: F(1,16) = 0.029, p = 0.98; SOD2 = stress effect: F(1,14) = 3.34, p = 0.095; treat-
ment effect: F(1,14) = 0.74, p = 0.4) (Fig. 6C,D), whereas SOD activity level was found significantly reduced in the 
CRS group (stress effect: F(1,8) = 5.44, p < 0.048;) and that this decrease was counteract by chronic Oxo treatment 
(treatment effect: F(1,8) = 5.0, p = 0.051) (treatment × stress effect: F(1,8) = 6.27, p < 0.037) (Fig. 6E). Chronic Oxo 
treatment counteracted SOD activity reduction in the CRS group, whereas chronic Oxo treatment alone did not 
produce any changes (Fig. 6E), contrarily to increase observed with acute Oxo treatment (Fig. 4E).
Discussion
Altogether, the present results indicate potential neuroprotective effects of acute Oxo due to its ability to reduce 
ROS and pro-inflammatory cytokines levels and to stimulate SOD activity. Interesting, these Oxo effects revealed 
a muscarinic modulation of ROS and pro-inflammatory molecules baseline levels in normal condition. This reg-
ulatory action toward pro-inflammatory factors seems to be specific, since Oxo treatment does not affect the 
anti-inflammatory IL-10 and TGF-β1. The results also highlight that chronic Oxo treatment may inhibit neuroin-
flammatory responses in the hippocampus of rats exposed to CRS.
Figure 3. Oxo effect on NF-κB-p65 and pNF-κB-p65 protein levels in the hippocampus. Cropped band-images 
of representative Western blot results of NF-κB-p65 and pNF-κB-p65 protein levels at different time-points 
(24, 48 and 72 h) after acute Oxo treatment. (A) NF-κB-p65 protein levels did not show changes following Oxo 
treatment as compared to control (Ctrl). (B) pNF-κB-p65 protein levels showed a significant decrease at 72 h 
after acute Oxo treatment as compared to control group. Full-length band-lines are presented in Supplementary 
Fig. S1. Data are reported as means ± SE. PLSD: *P < 0.05.
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Figure 4. Oxo effect on ROS levels and on SOD1 and SOD2 protein levels and activity in the hippocampus. 
Cropped band-images of representative Western blot results. (A) The analysis of global ROS levels following 
acute Oxo treatment revealed a significant decrease in all the studied time points (24 h, 48 h and 72 h) as 
compared to control group (Ctrl). (B) The selective analysis of 1O2 species levels following acute Oxo treatment 
revealed a significant decrease in all the studied time points (24 h, 48 h and 72 h) as compared to control group 
(Ctrl). The scopolamine (Scop), injected 20 min before of acute Oxo treatment, completely blocked Oxo effect 
on global ROS and 1O2 species levels. Scopolamine alone did not show significant changes of both global ROS 
and 1O2 species levels. (C,D) The analysis of SOD1and SOD2 protein levels at different time-points (24 h, 48 h 
and 72 h) revealed a significant increase only for SOD2 at 72 h as compared to control group. Scopolamine 
pretreatment completely blocked the increase of SOD2 protein levels. The group treated with scopolamine alone 
did not show significant change of SOD1 and SOD2 protein levels. (E) The analysis of SOD activity evidenced 
a significant increase of SOD activity at 48 h and 72 h after acute Oxo treatment as compared to control group. 
Scopolamine pretreatment completely blocked Oxo effect on SOD activity. Scopolamine alone did not show 
significant changes of SOD activity as compared to control group. Full-length band-lines are presented in 
Supplementary Fig. S2. Data are reported as means ± SE. PLSD: **P < 0.01, ***P < 0.001, ****P < 0.0001.
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As already indicated in the introduction section, only two papers are available in the context of 
anti-inflammatory Oxo effects and both reported the scopolamine-mediated elevation of TNF-α and the stimu-
lation of NF-κB pathway in the rat hippocampus11 and in immortalized murine microglia BV-2 cell12. Therefore, 
Figure 5. Pro-inflammatory and anti-inflammatory cytokine levels, including NF-κB-p65, in the hippocampus 
of rats exposed to CRS and their regulation by chronic Oxo treatment. ELISA analysis of IL-1β (A) and IL-6 
(B) protein levels revealed a significant increase in CRS group. The chronic Oxo treatment completely blocked 
CRS effect on IL-1β and IL-6. Oxo treated group did not show significant changes of both IL-1β and IL-6. The 
ELISA analysis of IL-10 (C) and TGF-β1 (D) protein levels did not show significant variation in all experimental 
groups. (E) Cropped band-images of representative Western blot results. The analysis of NF-κB-p65 protein 
levels did not show significant changes in all experimental groups. Full-length band-lines are presented in 
Supplementary Fig. S3. Ctrl, Control group. Data are reported as means ± SE. t-test: *P < 0.05, ***P < 0.001.
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Figure 6. ROS levels, SOD1 and SOD2 protein levels and activity in the hippocampus of rats exposed to CRS 
and their regulation by chronic Oxo treatment. (A) The analysis of global ROS levels revealed increased levels 
of ROS in the CRS. Treatment of CRS group with chronic Oxo failed to counteract the ROS increase. (B) The 
selective analysis of 1O2 species levels revealed a significant increase in the CRS. Treatment of CRS group 
with chronic Oxo failed to counteract the 1O2 species increase. The group treated with Oxo alone showed a 
significant increase of 1O2 species levels as compared to control group. (C,D) The Western blotting analysis 
showed unchanged levels of SOD1 and SOD2 protein in all experimental groups. Cropped band-images are 
representative of Western blot results. Full-length band-lines are presented in Supplementary Fig. S4. (E) SOD 
activity level was found significantly reduced in the CRS group. Chronic Oxo treatment counteracted SOD 
activity reduction in the CRS group. Group treated with Oxo alone did not show any variations as compared to 
control group (Ctrl). Data are reported as means ± SE. t-test: *P < 0.05, ***P < 0.001, ****P < 0.0001.
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the anti-inflammatory action observed in the present study by activation of mAChRs is consistent with the 
pro-inflammatory effects observed by previous studies with mAChRs antagonist scopolamine. However, in the 
present investigation we found that the treatment with mAChR antagonist scopolamine alone does not affect any 
of the studied cytokines.
In the hippocampus, IL-1β is released mainly by microglia but also by neurons and astrocytes39. Concerning 
IL-1β function, in addition to its pro-inflammatory role, low expression levels are involved in learning and mem-
ory, while chronically elevated IL-1β levels reduced memory and cognition40,41. Our observation of the inhibitory 
effect of mAChR activation on IL-1β baseline levels suggests a new mechanism through which the cholinergic 
system may regulate learning and memory.
Despite the fact that astrocytes and microglia are the main producers of IL-6 in the brain42, neuronal cells 
can also produce IL-6 in brain disease and injury or following prolonged neuronal activity43. Although several 
experimental conditions have shown up-regulation of IL-6 levels in glial cells and neurons44, no data are available 
on mAChR activation. IL-6 was found increased during neuroinflammatory response, such as brain infection 
and injury or in several brain diseases44. However, IL-6 was also found involved in the normal brain functions. 
For example inhibition of IL-6 expression produced improvement of long-term memory, suggesting a negative 
regulation of IL-6 in memory formation. As support to these results, mice with up-regulated IL-6 levels in the 
brain show impaired cognitive functions and deficits in learning45. In this study, the observed down-regulation of 
IL-6 in the hippocampus mediated by mAChR activation could then suggest new mechanism through which the 
cholinergic system may regulate learning and memory. However, from an anti-inflammatory point of view, this 
reduction of both IL-1β and IL-6 could explain the hypothesis, proposed by Borokivova46, according to which 
ACh levels decrease can favor neuroinflammatory events, as observed in Alzheimer disease.
On the contrary, TGF-β1 and IL-10, actively involved in anti-inflammatory responses47,48 were not regulated 
by mAChR activation, suggesting a mAChR selective regulation of pro-inflammatory cytokines rather than 
anti-inflammatory ones.
Neuronal cells possess substantial constitutive NF-κB activity, which can be triggered not only by cytokines 
or physical stressors, but also by neurotransmitters, such as glutamate49,50 and, as shown here, cholinergic 
agonists. Stimulation of mAChR by carbachol has previously been showed to induce activation of NF-κB in 
SH-SY5Ycells51. NF-κB plays a key role in the regulation of the inflammatory response, controlling the transcrip-
tion of pro-inflammatory genes by synthesizing cytokines, including IL-1β and IL-652. Therefore, the reduced 
levels of pNF-κB-p65 following Oxo treatment showed a good correlation with inhibitory action on IL-1β and 
IL-6 levels. Alternatively, since NF-κB may be activated by IL-1β53 or by ROS54, the reduction of IL-1β and ROS 
levels found in the present work could be responsible for pNF-κB-p65 reduction. Further experiments will be 
needed to examine the possible mechanism of NF-κB-p65 regulation by Oxo and to examine other cell signaling 
involved in the Oxo effects.
It is known that deficit of oxidants neutralization leads to an accumulation of oxidative free radicals and ROS 
that generate oxidative stress and cellular dysfunction55. In the present study we found a long lasting, up to72 h, 
significant reduction of global ROS levels following single Oxo injection. This result highlight that Oxo treatment 
may exert anti-oxidative action in the hippocampus, suggesting that it may protect cells against oxidative stress. 
Among ROS, we have examined the 1O2 species levels, as one of ROS with high oxidative and cytotoxic effects56,57. 
Interesting, the data obtained measuring 1O2 species levels showed a good overlap with those found analyzing 
global ROS levels, thus suggesting that 1O2 species generation can be one of ROS regulated by Oxo treatment. 
Concerning the role of mAChRs in brain responses to oxidative stress, only few and, in addition, discordant data 
are available. Indeed, some data reported that mAChR activation increases neuronal vulnerability to oxidative 
stress13, while others that mAChR stimulation can generate ROS, involved in neuronal-signaling pathways14,15. 
Recently, two different research groups reported that scopolamine administration induced memory deficit and 
increased ROS levels58,59, in agreement with the present data showing a significant reduction of ROS levels at 
all-time points following acute Oxo treatment. In contrast, here we have not found significant ROS levels change 
in the rat group treated with scopolamine, probably due to different timing of ROS level detection, i.e. few hours 
versus 72 h after scopolamine treatment.
The protection against oxidative stress needs several antioxidant enzymes such as SOD, in both its cytosolic 
SOD1 and mitochondrial SOD2 form, which catalyze the dismutation of superoxide anion (O2−) to oxygen and 
hydrogen peroxide (H2O2), thus exerting protective actions against oxidative stress60. In this study, we evidenced 
an increase of both SOD2 protein and SOD activity following Oxo treatment, and this antioxidant SOD activity 
appears consistent with the reduced ROS levels. Based on this result and in line with literature data showing 
high production of ROS in mitochondria, it is possible to make the hypothesis that mAChR activation decreases 
mitochondrial ROS levels through the up-regulation of SOD2. This possibility could be relevant in mitochondrial 
protection against injury produced by oxidative stress. Previous data showed that ACh may have neuroprotective 
role against oxidative stress- by enhancing the protein expressions and activity of SOD61, and that ACh levels 
are positively correlated with SOD levels62. Moreover, antioxidant enzyme activities, including SOD activity, are 
decreased in rat hippocampus following scopolamine injection63. Taken together, the reduction of ROS levels and 
the increase of SOD activity suggest a protective role of mAChRs activation against oxidative stress.
mAChRs family presents five subtypes receptors (M1R–M5R) and, among them, M1R, M3R and M5R are cou-
pled to Gαq/11 family of G proteins and preferentially signal by phospholipase C activation, whereas the M2R and 
M4R, are coupled to Gαi/o family of G-proteins, and mainly signal by adenylyl cyclase V inhibition1. The subtype 
receptors expressed in the hippocampus are M1R, M2R and M3R, with high levels of M1R in neurons64,65 and 
M3R in glial cells66–69. The M2R and M4R are present in the molecular layer8,70 and M5R in CA1-CA2 Pyramidal 
neurons and in the subiculum71. In addition, M1R, M2R and M3R are present at both presynaptic and postsynaptic 
level and are involved in hippocampal synaptic plasticity72 contributing to the learning and memory processes1.
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In general, activation of these mAChRs in the hippocampus regulates several functions such as synaptic plas-
ticity, neuro-survival, cognitive responses and behaviors6–8,18, including stem cell proliferation and apoptosis73,74. 
Indeed, treatment with mAChR agonist carbachol sinduces proliferation of neural progenitor cells75, while sys-
temic administration of pilocarpine exerts neuroprotective effects76. In addition, mAChRs activation may protect 
against apoptosis both by inducing PI3-kinase and by increasing anti-apoptotic proteins77 and can regulate adult 
hippocampal neurogenesis as well as improve behavioral deficits induced by stress, as reported by Veena et al.17. 
Although a specific study is needed to find out the subtype of mAChR and the related signaling involved in the 
observed effects of Oxo treatment, we tentatively can hypothesize the involvement of M1R, based on our pub-
lished data showing that M1R mediated the Oxo-induced FGFR1 transactivation associated to neuronal axonal 
growth8.
Among glial cells, both microglia67,68 and astrocytes66,69 respond to the mAChR agonist carbachol controlling 
glial cytokine release, phagocytosis and movement of processes including cell migration. Interesting, carbachol 
activation of microglia attenuates the release activity of pro-inflammatory cytokines78. Accordingly, here we could 
find a down-regulation of pro-inflammatory cytokines levels following mAChR activation by Oxo, which could 
correspond to reduced release of cytokines in glial cells. However, since we did not identify the cell type involved 
in Oxo effects, it is not possible to discuss whether the observed effects on cytokines in basal condition could 
come from the stimulation of neuronal cells or glial cells.
At molecular level, both anxiety and depression are characterized by dysfunctions of multiple systems, includ-
ing inflammatory mediators. Accordingly, several data support the link between the increase of inflammatory 
cytokines, such as IL-1β and IL-6, and the pathogenesis of mood disorders79. This emerging role of inflammation 
in the pathogenesis of depression and anxiety has recently attracted increasing interest on the immune-regulation 
properties of drugs showing antidepressant effects. Since in previous study we showed the ability of Oxo treat-
ment to abolish the anxiety-like behavior induced by CRS7, the findings of the present work clearly showed that 
chronic Oxo treatment may counteract the CRS effects on IL-1β and IL-6 levels. This finding correlates with the 
inhibitory effect of Oxo on IL-1β and IL-6 observed following acute Oxo treatment. However, IL-1β and IL-6 lev-
els were unchanged in the group treated for 10 days with Oxo alone, as compared to control, thus indicating that 
chronic Oxo treatment loses the effect observed in the acute Oxo treatment. For this result we hypothesize that 
mAChR receptor submitted to chronic stimulation can develop adaptation or inhibition by receptor desensitiza-
tion or internalization and downregulation. In line with this hypothesis, it has been demonstrated that chronic 
stimulation of mAChRs induced uncoupling of the receptor from the G protein and receptor internalization or 
desensitization in different cell types80,81. Ligand-induced receptor internalization by prolonged receptor activa-
tion is relevant mechanism in regulating cellular response82, particularly since most drug therapies need a chronic 
treatment.
Numerous investigations using various animal model of anxiety-like behavior have shown pro-inflammatory 
effects in the brain. Variation of NF-κB, IL-1β, and IL-6 have been found in rats model anxiety-like behavior 
induced by food deprivation83 or by several stressors, including CRS, enhancing the inflammatory profile of 
microglia84. Moreover, CRS differentially regulates inflammation in mice, including IL-685, and exposure to acute 
stress induces IL-1β protein in different brain regions in the rat27. Further, unpredictable chronic mild stress 
inducing depressive states increases pro-inflammatory cytokines levels, such a IL-1β and NF-κB in the hippocam-
pus86, and maternal care deprivation increases IL-1β, IL-6 and TNF-α, whereas reduces the anti-inflammatory 
cytokine IL-10 level. All together these results are in line with the present data showing that CRS may induce 
IL-1β and IL-6. However, in this CRS model, we did not find variation of NF-κB-p65 or IL-10 and TGF-β1 protein 
levels.
In line with the inflammation hypothesis of anxiety-depression, anxiolytic and antidepressant effect of several 
drugs has been linked to a down-regulation of pro-inflammatory cytokines in the rat hippocampus29. For exam-
ple, antidepressant agomelatine counteracts the LPS-induced up-regulation of IL-1β and IL-6 in the rat brain, 
and this effect seems to be mediated by inhibition of NF-κB translocation87. In this context, as already reported 
in the introduction, antidepressant effect of ketamine and β-adrenergic receptor antagonist has been associated 
with inhibition of pro-inflammatory responses30,31,35 and antidepressant fluoxetine may reduce the production 
of IL-1β36. All together these results support the present data revealing that treatment with Oxo, endowed with 
anxiolytic property7, may regulate IL-1β and IL-6.
Experimental studies have evidenced that oxidative stress is involved in the pathogenesis of anxiety and 
depression38,88. In the present study, we found increased ROS levels and reduced SOD activity in the CRS group. 
However, treatment with Oxo failed to counteract the increase of ROS in the CRS model, which might be likely 
dependent on specific molecular signals that characterize oxidative stress in the CRS model and that are out of 
Oxo treatment control. Further, the control group treated with chronic Oxo alone was also unable to show inhib-
itory effects on ROS levels, unlike the case of acute Oxo treatment. Interesting, it has been showed that chronic 
stress may decrease the activity of antioxidant enzymes in rat brain89. Accordingly, here we found that chronic 
Oxo treatment counteracted SOD activity reduction observed in the CRS group. However, in contrast to acute 
Oxo treatment, SOD activity levels were unchanged in the rat group treated with Oxo alone. Such lack of effect 
in the ray group treated with Oxo alone in the chronic versus acute treatment might be attributed, as already dis-
cussed above, to mAChR desensitization or internalization and downregulation after chronic treatment.
It is known that glucocorticoids, including cortisol, exert anti-inflammatory action and therefore may inter-
fere with the observed data following treatment with Oxo. In fact, the glucocorticoid receptor, highly expressed 
within the rat hippocampus90, has been reported to influence NF-κB signaling pathway and to inhibit the expres-
sion of several cytokines genes including IL-1β itself91. However, in the present work, the evaluation of cortisol 
levels after acute Oxo treatment has shown a trend of reduction in all the examined time-points. Therefore it is 
possible exclude the possibility that the antioxidant effect and the reduced levels of IL-1β and IL-6 observed after 
acute Oxo treatment can be dependent on cortisol levels.
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Concerning the CRS model we observed a trend of cortisol levels increase in all experimental groups, but in 
none of them it becomes significant. Therefore for pro-inflammatory cytokines restored to control levels in the 
CRS group after chronic Oxo treatment, we can exclude that the Oxo anti-inflammatory effect might be depend-
ent on cortisol levels. On the other hand, pro-inflammatory cytokines were found increased in the CRS group and 
unchanged in the Oxo group despite the trend of cortisol levels increase.
Conclusion
These results indicate a potential anti-inflammatory and antioxidant effect of acute Oxo treatment due to its 
ability to regulate pro-inflammatory cytokine and ROS levels and to increase SOD activity. Interesting, this 
downregulation exerted by Oxo on basal levels of IL-1β and IL-6 and on oxidative stress, reveals a muscarinic 
modulation of these pro-inflammatory molecules in normal condition. In the present study, we also showed 
that chronic Oxo treatment might exert some anti-inflammatory action in the hippocampus of rat exposed to 
CRS-induced anxiety-like behavior, revealing that mAChR activation, in addition to anxiolytic properties7, may 
have anti-inflammatory action. Taken together, these data suggest that mAChR agonist Oxo could potentially be 
used in the treatment of inflammatory component of anxiety-depression and neurodegenerative diseases, such 
as Alzheimer’s disease.
Materials and Methods
Animals care. Here we report standard information, similar to those reported in all our published papers, 
about the animal care and rules for the experimental use of mammals. Rats were housed in a specific patho-
gen-free environment, three per polypropylene cages in controlled temperature (23 ± 2 °C), humidity (50–55%) 
and light (12-h light/dark cycle), with access to food and water ad libitum.
The experiments were carried out in accordance with the National Institute of Health Guidelines for the Care 
and Use of Mammals in Neuroscience and Behavioral Research (The National Academics Press, WA, USA), with 
the rules and principles of the European Communities Council Directive 2010/63/EU revising Directive 86/609/
EEC, in accordance with the national D.L. March 4, 2014, no. 26, and were approved by the local Animal Care 
Committee (OPBA) of University of Palermo, Italy and Ministry of Health, Italy. No other methods to perform 
the described experiments (3Rs) were found.
Experimental design of acute Oxo treatment. Adult male Wistar rats (4 months old) were used. In 
the present work we used the following experimental groups, including 5 animals for each group: (1) control 
group treated with vehicle saline 0.9% (Ctrl); (2) acute Oxo treated group with a non-selective mAChR ago-
nist Oxotremorine M (Oxo) (Oxotremorine 100, Sigma-Aldrich Chemical Co. St. Louise, MO, USA), receiv-
ing only one Oxo injection (0.4 mg/kg); (3) group pretreated with 1 mg/kg of mAChR antagonist scopolamine 
(Scopolamine hydrobromidetrihydrate, Sigma-Aldrich Chemical Co) given 20 min before Oxo (0.4 mg/kg); (4) 
group treated with scopolamine alone (1 mg/kg). After the scheduled treatment, control and Oxo-treated rats 
were sacrificed at different time points: 24, 48 and 72 h. The groups pretreated with scopolamine plus Oxo and 
with scopolamine alone were restricted to the time point of 72 h. The experimental schedule is shown in Fig. 1A. 
The Oxo dose of 0.4 mg/kg for acute treatment has been chosen in relation to our previous experience9. Oxo and 
scopolamine were dissolved in 0.9% physiological saline solution before use and the scheduled dose was given 
intraperitoneally (i.p.) in a volume of 0.2 ml, as well as saline treatment. At the end of the experiment, the rats 
were sacrificed under deep anesthesia and following perfusion with cold PBS, used to remove the blood, the 
hippocampi were rapidly dissected from the rat brain, quickly frozen in cooled isopentane and stored at −70 °C 
for later use.
Part of experimental design, above described, was used in a previous paper9.
Experimental design of chronic Oxo treatment in the rat CRS model. This study was performed 
using the rat model of CRS previously adopted to induce anxiety-like behavior as reported in Di Liberto et al.7. 
Briefly, the CRS procedure was carried out once daily for 6 h and for 21 consecutive days. Rats were placed in a 
transparent plastic restrainer (350 ml cubage water bottle, 20 × 7 cm) with several 3 mm holes for breathing. After 
21 days of CRS the experimental groups were treated for 10 days with Oxo or vehicle saline according to the below 
mentioned groups. Oxo at dose of 0.2 mg/kg was given i.p. in a volume of 0.5 ml, as well as vehicle saline treat-
ment. For chronic Oxo treatment we used the dose of 0.2 mg/Kg instead of that used for acute treatment, both in 
relation to our previous experience7,9 and literature data17,92 and to previous preliminary test, in which the chronic 
treatment with the dose of 0.2 mg/Kg was better tolerated by the animals compared to 0.4 mg/kg.
The following experimental groups, with 5 rats for each group, were used: (i) control unstressed group treated 
with vehicle saline (Ctrl); (ii) chronic restraint-stressed group treated with saline (CRS); (iii) restraint-stressed 
plus Oxo-treated group (CRS + Oxo); (iiii) unstressed group treated with Oxo (Oxo). The experimental schedule 
is shown in Fig. 1B. After the experimental procedures, rats were sacrificed by deep anesthesia and hippocampi 
were removed from brain for the detection of inflammatory and oxidant marker levels.
Western blotting. Western blotting was performed as previously described by Frinchi et al.93. Dissected hip-
pocampal tissue was homogenized in cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, pH 7.4, 
150 mM NaCl, 1% Triton, SDS 0.1%), supplemented with protease inhibitor cocktail (Sigma-Aldrich P8340) and 
phosphatase inhibitor cocktail (Sigma-Aldrich, P5726). Samples were sonicated (30 pulsations/min), quantified 
by the Lowry method94 and stored at −80 °C. Protein Samples (30–50 μg per lane) and molecular weight marker 
(161-0376 BIO-RAD) were run on 10% polyacrylamide gel and electrophoretically transferred onto nitrocellulose 
membrane (RPN303E, Hybond-C-extra, GE Healthcare Europe GmbH). The membranes were incubated for 1 h 
in blocking buffer (1x TBS, 0.1% Tween-20, 5% w/v nonfat dry milk) and incubated with gentle shaking over-
night at −4 °C with specific antibody diluted in blocking buffer. For detection of NF-κB, phosphorylated NF-κB 
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(pNF-κB), SOD1 and SOD2, as already described in Mudò et al.95, the following antibodies and procedures were 
used: rabbit polyclonal anti-NF-κB-p65 subunit 1:500 (SC-372 Santa Cruz Biotechnology);mouse-monoclonal 
anti-pNF-κB-p65 1:500 (Sc-136548 Santa Cruz Biotechnology); rabbit polyclonal anti-SOD1 1:1000 (Sc-11407 
Santa Cruz Biotechnology); mouse anti-SOD2 1:500 (SOD2; sc-137254, Santa Cruz Biotechnology). The day after, 
membranes were washed three times for 10 min with TBS/T and incubated for 1 h at room temperature with goat 
anti-Rabbit IgG (sc-2004 Santa Cruz Biotechnology) or goat anti-mouse IgG (Sc.7076 Cell Signaling Technology) 
horseradish peroxidase-conjugated diluted 1:10000. After three washings with TBS-T, immunocomplexes were 
visualized with chemiluminescence reagent (RPN2236, GE Healthcare Europe GmbH) according to the man-
ufacturer’s instructions. The Hyperfilm (ECL-films 28906837, GE Healthcare Europe GmbH) were developed 
using Kodak developer and fixer (catalog no. 1900984 and 1902485, Kodak GBX, Eastman Kodak). For the nor-
malization of quantitative evaluation of bands each membrane was stripped at 65 °C for 30 min in buffer con-
taining NaCl 137 mM, TrisHCl 20 mM pH 7.6 and β-mercaptoethanol 0.01%. After two washings with TBST, the 
membranes were reprobed with anti-β-Actin antibody (sc-47778, Santa Cruz Biotechnology). The densitometric 
evaluation of bands was performed by measuring the optical density (O.D.) using the Image J software (Rasband 
WS, ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997–2018). 
All uncropped images are presented in Supplementary Figs S1–S4.
Measurement of pro-inflammatory or anti-inflammatory cytokines by ELISA-assay. 
Concentrations of IL-1β, IL-6, IL-10 and TGF-β1 were measured in the hippocampus homogenates (20 mg of tis-
sue sample) using enzyme-linked immunosorbent assay (ELISA) kits for rat (Cloud-Clone Corp, Wuhan, Hubei) 
according to the manufacturers’ protocols and as reported in Zizzo et al.96 and in Mudò et al.95.
ROS analysis. The procedures described here are found in previous papers95,97, in order to asses ROS gener-
ation we used two fluorescent probes: (1) dichlorofluorescein diacetate (DCFH-DA); (2) Singlet Oxygen Sensor 
Green (SOSG). (1). The nonselective DCFH-DA probe was used to asses several ROS generation, mainly includ-
ing hydrogen peroxide (H2O2), hydroxyl radical (*OH) and peroxyl radical (ROO*), a lipid peroxide associated 
to the cellular membrane. Therefore, we used the DCFH-DA assay as adequate procedure to measure the global 
variation of ROS levels and reveal cell oxidative stress98. Tissue from rat hippocampus (10 mg) were suspended 
on 1000 µl of PBS1X with 10 μl of protease inhibitors (Amersham Life Science, Munich, Germany). Then, samples 
were incubated with 1 mM dichlorofluorescein diacetate (DCFH-DA) for 10 min at room temperature in the dark. 
The conversion of non-fluorescent DCFH-DA to the highly fluorescent compound 20,70-dichlorofluorescein 
(DCF) by esterase activity was used to monitor the presence of peroxides due to the oxidative burst in the brains. 
Therefore, the emitted fluorescence is directly proportional to the concentration of ROS. The samples were ana-
lyzed by fluorimeter (Microplate reader WallacVictor 2–1420 MultilabelCounter; PerkinElmer, Inc.), using the 
excitation filter set at 485 nm and the emission filter set at 530 nm. Relative ROS production was expressed as the 
change in fluorescence of experimental groups compared with that of the appropriate controls (100%). (2) The 
SOSG probe, which is considered to be highly selective and sensitive singlet oxygen (1O2) indicator99,100, although 
some criticism about sensitivity101, was used to selectively evaluate the 1O2 species generation. We have chosen 
to evaluate the 1O2 species generation as one of ROS with high oxidative and cytotoxic effects56,57. To valuated 
the level of 1O2, 10 mg of tissue from rat’s hippocampus was weighed and homogenate on 1000 μl of PBS1X. 
After homogenizing the sample tubes were centrifuged at 10,000 g at 2 °C for 5 min. 48 μL of supernatant of each 
sample was mixed with 50 μL of the reagent buffer and 2 μL of 5 mM of SOSG agent (Molecular Probes, USA). 
80 μL of each sample mixture was added into a well of 96-well plate (Black Microtiter Plate, Thermo Scientific, 
Finland) and covered with transparent lid. The fluorescence signal was measured at excitation 488 nm and emis-
sion 525 nm by a spectrophotometer GloMax® Discover System (Promega, USA).
SOD activity levels. The procedure described here is reported in Mudò et al.95. The Hippocampus of rats 
was homogenized in PBS with protease inhibitors (Amersham Life Science, Munich, Germany). To remove insol-
uble material, tissue lysates were sonicated and centrifuged (14.000 rpm, at 4 °C, for 30 min). In the supernatant, 
total proteins were quantified by Bio-Rad Bradford Protein Assays. Volume corresponding to 50 μg of protein 
were used for total SOD enzymatic activity measurement, by using the SOD assay kit (Sigma-Aldrich) according 
to manufacturer’s instructions. Absorbance was measured by using the iMark™ Microplate Absorbance Reader 
at 450 nm.
Cortisol levels. The procedure described here is reported in Mudò et al.95. Rats of all the experimental groups 
were decapitated under deep anesthesia between 11:00–12:00 am and blood was collected in tubes coated with 
EDTA. Blood samples were centrifuged at 4,000 × g at 4 °C for 10 min and the supernatant was stored at −80 °C. 
The plasma levels of cortisol were measured using automated electrochemiluminescence immunoassay (Roche 
Diagnostics Elecsys Cortisol II assays and COBAS E801) and values were expressed in ng/ml. The minimum level 
of detection for assays of cortisol was 0.15 ng/ml.
Statistical analysis. The statistical analysis procedure used was described in Mudò et al.95. The results are 
presented as mean ± SE, and in some case are expressed as arbitrary units, with controls equal to 1, or as percent-
age of control. Statistical evaluation was performed by one-way ANOVA, followed by Fisher’s Protected Least 
Significant Difference (PLSD) test. Two-way analysis of variance (ANOVA) was performed to assess the main 
effect of CRS (stress) and Oxo treatment (treatment), and the interaction (stress × treatment). When ANOVA 
was found significant, intra- and inter-group differences were measured by student t-test. Differences in P-value 
less than 0.05 were considered statistically significant.
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